Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Initial Beneficial Ownership · 3/A

AC Immune SA

ACIUNASDAQEQUITYCurrent

Initial Beneficial Ownership

Filed Oct 9, 2026Accepted Oct 9, 2026, 5:22 PM EDTFiling CIK 1651625Accession 0000950103-26-015456
Share

Structured filing — 3/A

ownership.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Filing details

Report period
2026-10-02
Original submission
2026-10-09
Issuer
AC Immune SA
Issuer CIK
0001651625
Trading symbol
ACIU

Reporting owner 1

Name
Graney Thomas
Reporting owner CIK
0001618275
Relationship
Director
Address
EPFL INNOVATION PARK, BUILDING B, LAUSANNE, SWITZERLAND, V8, 1015

Non-derivative holdings

Non-derivative holdings · 1 reported row
SecurityAmount ownedOwnership
Common Shares12,959[F1]D
Table key
D
Direct

Derivative holdings

Derivative holdings · 1 reported row
SecurityConversion / exercise priceExercisableExpiresUnderlying securityUnderlying sharesOwnership
Share Option (right to buy)2.712027-06-102036-10-01Common Shares19,565D
Table key
D
Direct

Footnotes

F1
Includes 8,936 common shares underlying outstanding restricted share units.↩ 1

Remarks

Exhibit 24 - Power of Attorney. This Form 3/A is being filed solely to add a copy of the Power of Attorney as Exhibit 24.

Signature 1

Signed
/s/ Matthias Maurer, attorney-in-fact for Thomas Graney
Date
2026-10-09

Filed exhibits

Company context

AC Immune (NASDAQ: ACIU) is a clinical-stage biopharma company selectively targeting the key pathologic misfolded proteins and pathways that drive neurodegenerative diseases. Building on more than two decades of expertise in the field of misfolded proteins, AC Immune is advancing a diversified portfolio of disease-modifying active immunotherapies and small molecule approaches. AC Immune’s wholly-owned pipeline includes its lead program, ACI-7104, in Phase 2 development for early Parkinson's disease (PD), a progressive neurodegenerative disease affecting c.10 million people worldwide with no approved disease-modifying therapies today. By targeting misfolded alpha-synuclein, a key driver of PD progression, ACI-7104 aims to slow, or halt, the spread of the disease throughout the brain before irreversible neurological damage occurs. The Company is also advancing ACI-19764, an NLRP3 inflammasome inhibitor in Phase 1, and a preclinical intracellular small molecule alpha-synuclein program.

Current securities

Recent company filings

  1. 6-K filingNov 4, 2026
  2. 3 filingOct 9, 2026
  3. 6-K filingOct 2, 2026
  4. 6-K filingSep 23, 2026
  5. 6-K filingSep 3, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.